Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
Date:7/19/2011

SHANGHAI, July 19, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2011 after the New York Stock Exchange closes on Wednesday, August 10, 2011 (which will be Thursday morning, August 11, 2011 Shanghai time). The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Thursday, August 11, 2011, to discuss the second-quarter 2011 financial results and recent business activities. The conference call may be accessed by calling:United States:

1-866-519-4004China (Landline):

800-819-0121China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381Conference ID:

83583576A telephone replay will be available two hours after the call's completion at:

United States:

1-866-214-5335China North:

10-800-714-0386China South:

10-800-140-0386Hong Kong:

800-901-596United Kingdom:

0-800-731-7846International:

+61-2-8235-5000Conference ID:

83583576A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com.

About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald AldridgeDirector of Investor RelationsWuXi PharmaTech (Cayman) Inc.Tel: +1-201-585-2048Email: Ron_Aldridge@wuxiapptec.comWeb: http://www.wuxiapptec.com
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
10. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
11. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):